Bridgeway Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bridgeway Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Hold	77,300	–	–	0.01%	923
2026 Q1	$181K	Hold	77,300	–	–	﹤0.01%	1052
2025 Q4	$104K	Hold	77,300	–	–	﹤0.01%	1119
2025 Q3	$117K	Hold	77,300	–	–	﹤0.01%	1091
2025 Q2	$89.7K	Sell	77,300 -75,000	-49%	-$98.9K	﹤0.01%	1089
2025 Q1	$242K	Sell	152,300 -22,700	-13%	-$49K	0.01%	879
2024 Q4	$530K	Buy	+175,000	New	+$574K	0.01%	802

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Bridgeway Capital Management's ZNTL Position: Q2 2026 in Review

Bridgeway Capital Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 77,300 shares worth $375K. The position accounts for 0.01% of the portfolio, ranked #923.

Bridgeway Capital Management first reported a position in ZNTL in Q4 2024 and has held it in 7 quarters since. The position peaked at $530K in Q4 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

Bridgeway Capital Management held 77,300 shares of Zentalis Pharmaceuticals worth $375K as of Q2 2026.
Bridgeway Capital Management left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
Zentalis Pharmaceuticals made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #923 holding.
Bridgeway Capital Management first reported a position in Zentalis Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Bridgeway Capital Management's Zentalis Pharmaceuticals position peaked at $530K in Q4 2024.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.